Conference Proceedings

Ipilimumab plus nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab plus nivolumab in advanced non-clear cell renal cell carcinoma.

Craig Gedye, David William Pook, Laurence Eliot Miles Krieger, Carole A Harris, Jeffrey C Goh, Ganessan Kichenadasse, Howard Gurney, Craig Underhill, Francis Parnis, Anthony M Joshua, Tom Ferguson, Felicia Roncolato, Michelle L Harrison, Stephen Begbie, Michelle Frances Morris, Elizabeth J Hovey, Mathew George, Prashanth Prithviraj, Emma Link, Ian D Davis

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

Abstract

4565 Background: Immunotherapy targeting PD1 is active across many cancers, but many people are failed by PD1 inhibition alone. UNISON (ANZUP 1602/NCT03177239) has previously reported the activity and outcomes of nivolumab monotherapy in people with nccRCC (OTRR 17%, PFS6 45%; part 1), and here we report the outcomes of combining ipilimumab (I) and nivolumab (N), in people whose cancers are refractory to N alone (part 2). Methods: Participants (pts) with advanced nccRCC with good performance status (ECOG 0/1), were initially enrolled and took N alone. 41 pts refractory to N were offered the combination I (1mg/kg) + N (3mg/kg) every 3 weeks for up to 4 doses. Pts with disease control after N..

View full abstract